Labyrinthitis, Vestibular Neuritis and Sensorineural Hearing Loss (SNHL)

Michael AB Naafs
Naafs International Health Consultancy, Europe
Submission: April 09, 2018; Published: May 02, 2018
*Corresponding author: Michael AB Naafs, Internist-endocrinologist with a long clinical career in internal medicine and endocrinology, Naafs International Health Consultancy, Email: naafs.healthconsultancy@gmail.com

Abstract
This mini-review discusses pathogenesis and pathophysiology of vestibular neuritis, labyrinthitis and sensorineural hearing loss (SNHL). In addition, the role of the immune system as a therapeutic target in the treatment and course of these disorders is evaluated. Viral, bacterial, traumatic, congenital, acquired, and hereditary causes are discussed. Results of the therapeutic applications of glucocorticoids, immunosuppressives, and the new biologics are considered. Active target delivery of genetically modified monocytes seems at present the most attractive option for the treatment of SNHL if the surface of the delivery vehicle can be decorated with a ligand that selectively interacts with the target receptors.

Introduction
Vestibular neuritis and labyrinthitis are sometimes used interchangeably but "vestibular neuritis" should be confined to cases in which the vestibular nerve only is involved and the term "labyrinthitis" being used in cases in which the vestibular nerve and the labyrinth are affected. Vestibular neuritis is a very common cause of vertigo, labyrinthitis less so. Typically they produce disturbances of balance to varying degrees and may affect one or both ears. Essentially there is a sudden disruption of afferent neural input resulting in acute vertigo plus in the case of labyrinthitis, hearing loss [1].

Bacteria or viruses can cause acute inflammation of the labyrinth in conjunction with either local or systemic infections. Autoimmune processes may also cause labyrinthitis. Vascular ischemia may result in acute labyrinthine dysfunction that mimics labyrinthitis. Several mechanisms have been postulated as the pathophysiology of sudden deafness, including microthrombosis, microtrauma, or rupture of endolymphatic vessels, bacterial infection, and immune-mediated reaction.

In this mini-review, the pathogenesis, pathophysiology of these disorders are discussed. In addition, the immune system as a therapeutic target and the treatment and course of vestibular neuritis, labyrinthitis and sensorineural hearing loss (SNHL) will be evaluated.

Pathogenesis of peripheral vestibulopathy (PVP)

Viral causes: PVP is often preceded by a viral infection of the upper respiratory tract [5]. Herpes viruses in the eight and other cranial nerves were found as well in the saliva of patients [6-10]. Histopathological changes due to herpes viruses have been found in both the vestibular nerve and labyrinth [11]. HSV-1 has also been detected in the labyrinth [6]. The anatomical evidence of a vestibulofacial nerve anastomosis is one way of explaining those viruses in neurons [12]. However, the prevalence as described in those studies is insufficient to support herpes viruses as the only etiological factor. More likely, those findings point to the fact that PVP may have a multifactorial origin.

Often the case for the neuritis hypothesis (NH) is made by presenting PVP as analogous to Bell's palsy, which is also thought to be caused by a reactivation of viruses that subsequently leads to nerve edema and loss of function [6, 13]. However, how reasonable this may seem there are two differences. Firstly, corticosteroids have been found to be reasonably effective in the treatment of Bell's palsy [14] while their effect in treating PVP is less established [15, 16]. Other equally plausible agents should also be taken into account. For instance, herpes labialis, in which the reactivation of viruses, often proposed as a possible pathogenetic mechanism in PVP, leads to pathological changes in the skin. This would support a model with intralabyrinthine changes rather than an isolated neuritis.

Other evidence cited in favour of the NH includes MRI studies and histopathologic analyses. One MRI double case report mentions changes in the vestibular nerve but not in the labyrinth in two patients 7 and 11 days after symptom onset [17]. This study contradicts two others that looked at MRI of 8 and 60 patients with PVP and found no signs of a neuritis [18, 19]. Histopathological studies have found that there was evidence of viral infections and subsequent loss of neurons in the vestibular nerve. However, they also found significant changes in the labyrinth. There was "epithelization" on the otolith organs. This occurred in the maculae and the cristae of the SCCs (semicircular canals).
Bacterial causes: The advent of antibiotics and immunizations in the last century led to a considerable decline in the incidence of complications from otitis media and therefore a discussion on suppurative labyrinthitis with middle ear infection may seem, at first glance, an outdated issue. However, complications still occur, particularly in developing countries with significant morbidity resulting in hearing loss [21-26].

The diagnosis of suppurative labyrinthitis secondary to otitis media is essentially a clinical one through the observation of vertigo, nystagmus, tinnitus and hearing impairment in the presence of middle ear infection. In serous labyrinthitis symptoms are more subtle and many patients experience a satisfactory recovery with the treatment of underlying disorders of the middle ear. Little is known about the mechanisms involved in diseases of the human ear in vivo [27].

Imaging tests are important tools in an attempt to better understand the dynamics of inner ear inflammation. Currently the high-resolution computed tomography (HR-CT) best evaluates diseases affecting the inner ear and retrocochlear pathways. Recent advances in NMR technique offer interesting opportunities for the study of cochlear structure, function and metabolism in vivo. The use of gadolinium as a contrast for the study of the inner ear adds sensitivity to the NMR, particularly for diseases such as labyrinthitis [27-30].

Complications are labyrinthine fistula, meningitis, facial paralysis, mastoiditis, cerebral and temporal abscesses [31]. It is known that the sequence of events following an episode of suppurative labyrinthitis typically occurs in three stages. In the acute phase, bacteria and leukocytes appear in the perilymphatic space. In the fibrous phase, granulation tissue consisting of fibroblasts associated with neovascularization results in fibrosis. Finally the ossification phase is characterized by metaplastic bone formation [32]. In the radiological literature three phases of labyrinthitis are usually described as the acute, the fibrous stage and a Labyrinthitis ossificans. This division is however artificially and concomitantly occur of these phases is possible [33,34].

Moffat et al. assessed the frequency of bacterial agents in chronic suppurative otitis media and the antibiotic susceptibility patterns of isolates among patients (n=185). Staphylococcus spp. (64.9%) were the most prevalent bacteria isolated, followed by Kliebsiella spp. (12.9%) and Pseudomonas aeruginosa (10.3%).

The most effective antibiotic for treatment of bacterial chronic suppurative otitis media was ciprofloxacin. Statistical analysis showed no significant differences in bacterial infestations among chronic suppurative otitis media patients and the antimicrobial susceptibility patterns of the bacterial isolates based on gender and age (p>0.05) [35].

Recently, the draft protocol for a Cochrane review of the role of probiotics for preventing acute otitis media in children was released [36].

Pathogenesis SNHL

In developed countries approximately 80% of congenital hearing loss is due to genetic causes and the remainder to environmental. Acquired causes should be differentiated from genetic causes for the evaluation and required ancillary testing (i.e., CT/MRI and consultation with specialists) and to inform prognosis and treatment recommendations.

Acquired hearing loss in children commonly results from prenatal infections from “TORCH” organisms (i.e., toxoplasmosis, rubella, cytomegalovirus and herpes) or post-natal infections, particularly bacterial meningitis caused by Neisseria meningitidis, Haemophilus influenzae or Streptococcus pneumoniae. Meningitis from many other organisms including Escherichia coli, Listeria monocytogenes, Streptococcus agalactiae and Enterobacter cloacae can also cause hearing loss. In developed countries, however, the most common environmental non-genetic cause of congenital hearing loss is congenital cytomegalovirus (cCMV) infection. Its overall birth prevalence is approximately 0.64%. Ten percent of this number have symptomatic CMV which is characterized by a variable number and degree of findings including neurologic deficits (death, seizures, cerebral palsy), hepatic insufficiency and characteristic rash. Hearing loss affects approximately 50% of symptomatic individuals with cCMV. The remaining 90% of individuals with cCMV are considered “asymptomatic”. Of these up to 15% develop unilateral or bilateral hearing loss. Thus, the majority of individuals with hearing loss due to cCMV are classified as “asymptomatic” [37].

The diagnosis of CMV hearing loss can be difficult to make, often can go unrecognized and is characterized by variable severity bilateral asymmetric or unilateral sensorineural hearing loss [38]. Testing for cCMV requires a high degree of suspicion and should be done within 21 days of birth given the ubiquity of the virus in the environment. Recognizing cCMV hearing loss is increasingly important given new studies that show improvement of hearing loss with antiviral therapy for persons with symptomatic CMV [39]. To date, the use of antivirals to treat hearing loss in persons with cCMV whose only manifestation is hearing loss is experimental.

Acquired hearing loss in adults is most often attributed to environmental-genetic interactions the most frequent of which are age-related and noise-induced hearing loss. Although both of these types of hearing loss reflect complex “environmental-genetic” hearing loss, to date variants in only a few genes have...
been associated with these traits [40].

Approximately 80% of prelingual deafness is genetic, most often autosomal recessive. The most common cause of severe-to-profound autosomal recessive hearing loss in most populations is a mutation of GJB2. The most common cause of mild-to-moderate autosomal recessive hearing loss is a mutation of STRC [41].

**Autoimmunity and SNHL**

Immune-mediated inner ear disease has been introduced and accepted as a cause of SNHL. It responds to immunosuppressive therapy and is one of the reversible forms of bilateral SNHL. The concept of immune-mediated inner ear disease is straightforward and comprehensible but criteria for clinical diagnosis and the precise mechanism of hearing loss have not been determined. Moreover, the therapeutic mechanisms of corticosteroids are unclear [42].

Sensorineural hearing loss (SNHL) is a collection of common auditory disorders resulting from dysfunction of the inner ear auditory nerve or the auditory processing pathway in the central nervous system. SNHL comprises a wide variety of auditory disorders including sudden deafness, age-related hearing loss, noise-induced hearing loss, and Meniere’s disease. Until now very little of the pathophysiology is known because biopsy of the inner ear is not feasible. The cochlea has no lymphatic drainage and the blood-labyrinth barrier is tightly controlled to separate the cochlear microenvironment from the circulation. In addition, the concentration of immunoglobulin in the cochlear fluid is 1/1000 of the concentration in the cerebrospinal fluid [43]. McCabe introduced the clinical definition of autoimmune inner ear disease as rapidly progressive bilateral hearing loss that responds to corticosteroid and immunosuppressive therapy (4). Steroid-responsive hearing loss does not always indicate an underlying inflammation or immune disorder in the inner ear [44].

Topical application of corticosteroids in the tympanic cavity have also been reported in patients unable to tolerate systemic treatment [45, 46].

The pathophysiology of organ-specific autoimmune disease is believed to be initiated by three primary mechanisms:

a) Production of autoantibodies against tissue antigens
b) Deposition of antigen-antibody complexes in tissues
c) Infiltration and destruction of tissue by specific cytotoxic T-cells.

The mechanisms of hearing loss in immune-mediated inner ear disease has yet to be determined and none of the three described mechanisms have been reported in the human inner ear. Immune-mediated SNHL progresses to deafness over weeks or months, not hours, days, or years. The time course of hearing loss distinguishes immune-mediated inner ear disease from sudden deafness or age-related hearing loss. There are no uniformly accepted criteria of immune-mediated inner ear disease. The presence of bilateral SNHL of at least 30dB with evidence of progression in at least one ear or two serial audiograms performed less than 3 months apart is often used as case criteria [47]. Fluctuations in hearing loss may occur and immune-mediated disease is one of the few reversible causes of SNHL.

Multisystemic organ-nonspecific autoimmune pathology may involve the inner ear leading to secondary SNHL. A limited number of studies have evaluated temporal bones from patients with autoimmune disease such as Wegener granulomatosis, polyarteritis nodosa, Cogan syndrome and lupus (47, 48). Some specimen showed fibrosis and osteogenesis consistent with the end stage of inflammation. Other bones demonstrated atrophy of the stria vascularis, the organ of Corti and the spiral ganglion without evidence of inflammation. Dettmer et al. reported that the temporal bones of Crohn’s disease patients with granulomatous ear disease demonstrated mild chronic inflammation, poorly defined granuloma’s and infiltration of CD68-positive macrophages [49].

The first evidence for involvement of the immune system in SNHL was supported by studies of Rusk-Andersen and Stable. They showed intimate contact between lymphocytes and macrophages in the endolymphatic sac of guinea pigs [50]. This association suggested that two cell types mediated the antigen presenting process in the endolymphatic sac. The presence of immunocompetent cells and phagocytized antigen within macrophages was also reported in the endolymphatic sac [51].

However, recent studies have demonstrated the presence of immunoreactive cells in other areas of the inner ear even under normal conditions [52-54]. Lang et al. [52] reported that bone marrow-derived cells of hematopoietic origin migrate into the cochlea and reside in the cochlear modiolus and the cochlear lateral wall. They also showed that bone-marrow derived cells in the cochlea express ion transporters such as the sodium-potassium-chloride cotransporter or sodium-potassium-ATPase in the cochlear lateral wall, which contains several types of fibrocytes. In a study using bone marrow-chimeric mice that were transplanted with hematopoietic stem cells after receiving lethal systemic irradiation Okano et al. demonstrated that bone marrow derived cells reside as macrophages in the cochlea. They also reported that Iba-1 positive macrophages were continuously and slowly replaced by bone-marrow derived cells from the systemic circulation over several months [53]. Finally, Sato et al. reported that bone marrow-derived cells expressing CX3CR1, a fractalkine receptor specific to monocytes, natural killer cells, activated T-cells and tissue macrophages reside in the spiral ganglion and spiral ligament. In addition, they showed that CX3CR1-positive cells were repopulated in the cochlea over several months [54]. Collectively these findings indicate that the inner ear harbors immunocompetent cells of hematopoietic origin, which most cells likely to be tissue macrophages phenotypically.
The role of cochlear macrophages and mechanisms of macrophage migration into the cochlea remain largely unknown. The number of cochlear macrophages is also increased by systemic administration of macrophage colony stimulating factor (CSF-1) which is one of the primary regulators of mononuclear phagocyte activation. The density of Iba1-positive macrophages is increased in both the spiral ligament and spiral ganglion 1 day after administering CSF-1 but it is unclear whether the increased macrophage population is due to migration from the circulation or in situ proliferation in the cochlea [54]. Yagihashi et al. also demonstrated that topical administration of CSF-1 ameliorates the degradation of auditory neurons following surgical injury in a rat model [55]. In addition, CSF-1 was demonstrated to have neuroprotective properties in an in vitro model of excitotoxicity in hippocampal neurons, suggesting both direct and indirect effects of CSF-1 on survival of targeted cells [56].

Previous reports investigating in situ proliferation of cochlear macrophages are controversial. Using bromodeoxyuridine labeling Hirose et al. reported that cochlear macrophages do not proliferate after acoustic trauma [57]. However, according to the study done by Okano et al. a subset of macrophages expressed Ki67, suggesting that resident macrophages enter the cell cycle after migration following surgery of the cochlea [54]. Although the precise nature of migrating macrophages is to be determined, cochlear macrophages are most likely responsible for several different inner ear pathologies.

Macrophages are derived from monocyte precursors that undergo tissue-specific differentiation and infiltrate the site of infection or injury to produce inflammatory mediators. The cells typically polarize into the pro-inflammatory M1 phenotype and function as an effector of the Th-1 mediated immune response. The M1 polarization of macrophages is regulated by several factors including the mineralocorticoid receptor [58]. In the normal course of inflammation the immune process is controlled. M1 macrophages undergo apoptosis or switch to the anti-inflammatory M-2 phenotype thereby halting inflammation. However, if the inflammatory response of macrophages is not controlled it becomes pathogenetic. This results in significant levels of non-specific tissue damage and leading to inflammatory and autoimmune diseases [59]. Therefore, macrophage-targeted therapy is extremely relevant in improving the prognosis of inflammatory diseases, particularly inflammation in the inner ear.

Thought provoking observations have been made in studies of patients with human immunodeficiency virus (HIV) concerning macrophage function in the inner ear. Monocytes and macrophages are susceptible to HIV-infection and are considered a main mechanism responsible for control of nervous system infection in areas containing perivascular macrophages and parenchymal microglia [60]. Lin et al. [61] demonstrated that HIV infection is significantly associated with an increased risk of developing sudden deafness in patients aged between 18 and 35 years. In addition, Assuiti et al. found no direct association between anti-retroviral therapy and hearing loss [62]. These data suggest that deficiencies in the macrophage and monocyte lineage may lead to dysfunction in the inner ear and highlight the important role of macrophages in the maintenance of auditory function.

Several surface markers have been used in animal studies of macrophages to immunohistochemically test their phenotypes and distribution in the tissues. CD68 is a heavily glycosylated transmembrane protein and is a common surface marker expressed in all macrophages [63, 64]. F4/80 is a member of a gene family that includes the human epidermal growth factor module-containing mucin-like hormone receptor 1 and human CD97. They reside on the surface of a family of cells that includes all well differentiated members of the mononuclear phagocyte system. The precise function of F4/80 is not completely understood as F4/80 null mice have no remarkable phenotype. They have many common features regardless of their tissue location and are characterized by highly ramified cell shape [65]. Iba1 is a calcium binding protein specific to macrophages that mediates calcium signals that may control migration and phagocytosis in tissue macrophages [66]. Tissue macrophages in the inner ear express Iba1 inn addition to F4/80 [54]. Csf1r is an alternative surface marker on macrophages and is thought to play key roles in the proliferation, differentiation and survival of macrophages [65]. In other categorical systems, the differentiation of monocytes and macrophages is described as the expression of specific cell markers. If similar markers could be identified in tissue macrophages or cells of monocyte lineage it may be possible to trace these cells along several different points of the inner ear pathophysiology, including systemic circulating monocytes, migrating monocytes and resident tissue macrophages.

Systemic or possible local administration of corticosteroids is the mainstay of treatment for SNHL including immune-related inner ear disease. There are limited prospective data evaluating the appropriate dose, route and length of corticosteroid treatment. Although many patients experience a short-term response to steroids this response is generally not sustained [67]. A prospective, randomized, controlled study in 116 patients with rapidly progressive bilateral SNHL reported that 57% of patients in the 1 month prednisone challenge showed improved hearing but adverse effects as hyperglycemia were observed in 14% of patients [68]. A meta-analysis of the management of idiopathic sudden SNHL by Spear and Schwartz reported that intratympanic corticosteroids administered as the primary treatment appeared equivalent to treatment with high-dose oral prednisone [69]. Furthermore, intratympanic administration of corticosteroids potentially recovered some degree of hearing as a salvage therapy. These observations suggest that the local administration of corticosteroids is beneficial from that of systemic corticosteroid therapy.

Despite numerous clinical reports of corticosteroid treatment for SNHL, the spontaneous rate of recovery in acute
SNHL complicates conclusions about corticosteroid efficacy. The expression of glucocorticoid receptors in the inner ear is limited to the inner and outer hair cells, the spiral ganglion and the spiral ligament [70, 71]. In addition to glucocorticoid receptors, corticosteroids have a strong affinity for mineralocorticoid receptors. The use of systemic mineralocorticoids alone or in combination with glucocorticoids has not been evaluated in humans but is apparently efficacious in animal models [72]. Because the inner ear requires tight regulation of ion homeostasis in both the perilymph and endolymph, the effect of corticosteroid therapy through mineralocorticoid receptors should be considered in the mechanism of action when treating SNHL [4].

McCabe recommended high dose corticosteroids along with cyclophosphamide therapy for prolonged treatment of immune-mediated inner ear disease [4, 48]. The extended follow-up of patients treated with cyclophosphamide revealed potential adverse effects and long-term morbidity and mortality risks of the agent, particularly neoplasms development in younger patients which limited its use. This prompted the search for other immunosuppressive therapies [51, 73].

Methotrexate has been used as a sparing treatment to control refractory immune-mediated SNHL. Sally et al. reported improvement in the majority of 53 patients with immune-mediated inner ear diseases who were treated with low-dose methotrexate [74]. Long-term, low-dose methotrexate therapy appeared to be effective in at least some patients with immune-mediated hearing loss that is refractory to traditional corticosteroid therapy [75]. By contrast, a randomized, double-blind, placebo-controlled trial of immune-mediated inner ear disease suggested that methotrexate does not appear to be effective in maintaining the hearing improvement achieved with prednisone therapy [76]. Azathioprine was also reported as an alternative option in treating immune-mediated inner ear disease although reports were based on small case series and were inconclusive [77]. According to these findings, immunosuppressives such as methotrexate are effective in some patients with bilateral progressive or fluctuating SNHL. However, patients with bilateral fluctuating SNHL do not always have an immune disorder in the inner ear.

Molecular-targeted drugs and biological agents have attached attention due to their specificities against therapeutic targets resulting in less toxicity and fewer adverse effects. Etanercept is a fusion protein comprising two recombinant tumor necrosis factor (TNF) receptors linked to the C portion of human IgG1 [78]. A retrospective case series by Rahman et al. examined the response to etanercept in 12 patients with immune-mediated hearing loss responsive to high-doses of corticosteroids [79]. Improvement or stabilization of hearing and tinnitus was observed in 91% of patients suggesting that etanercept therapy is safe and may be efficacious in some patient’s immune-mediated hearing loss. By contrast, two studies reported that etanercept has no substantial efficacy in improving hearing loss [80, 81].

Infliximab is another monoclonal antibody against TNF-alpha that binds TNF-alpha and reduces its activity [82]. A retrospective review of eight patients with suspected immune-mediated hearing loss refractory to conventional treatment examined the efficacy of infliximab on hearing improvement. None of the patients showed a positive response to infliximab based on objective measurements [83]. Monoclonal antibody therapy directly targeting cells in the inner ear is unlikely to be effective because the concentration of immunoglobulin is much lower in this region than that in cerebrospinal fluid or blood due to the tight regulation by the blood-labyrinthine barrier. Accordingly, transympanic administration was evaluated by Van Wijk et al. in nine patients with immune-mediated hearing loss [84]. Transympanic administration of infliximab resulted in hearing improvement and reduced relapses indicating the potential utility of local administration of monocloaol antibody in treating inner ear disease. Adalimumab was also used to block TNF signalling in patients with immune-mediated hearing loss but reports were based on a small number of cases [85].

Rituxumab is a genetically engineered chimeric monoclonal antibody against CD20 which resides on the surface of B cells. The agent reduces autoantibody production both in circulating and tissue B cells but does not affect plasma cells. A small pilot study in patients with immune-mediated inner ear diseases was performed evaluating the efficacy of rituxumab in treating hearing loss [86]. Further evaluation of rituxumab is encouraged using a properly designed study.

Nucleic acid therapy, including delivery of gene constructs to increase or force expression in the targeted tissue and small interfering RNA to block expression of a specific gene, is a promising approach for treating inner ear disease. Limited access to the lesion site creates challenges in nucleic acid therapy of the inner ear. Various studies employing animal models utilize viral vectors to introduce the nucleic acid in the inner ear. There are toxicity and safety concerns associated with this method including immunogenicity and mutagenesis. Non-viral vectors are advantaged by overcoming these limitations plaquing viral vectors. Although nucleic acid therapy is challenging in the in vivo setting, the development of novel delivery systems could lead to drastic advances in improving the prognosis of patients with SNHL. Obviously, macrophages are a potential target for nucleic acid therapy using novel delivery systems in the inner ear, controlling not only inflammation and degeneration of sensory organs but also regeneration of the cochlear lateral wall and innervation from the spiral ganglion neurons to hair cells.

The use of genetically modified monocytes or macrophages as vectors should be considered for production of therapeutic molecules or factors that promote regeneration or regrowth of specific structures in the inner ear. This concept is especially well suited for a secreted paracrine or endocrine factor such as a hormone or growth factor. Because the inner ear contains three fluid-filled compartments, secreted factors from genetically modified macrophages could potentially diffuse throughout the...
inner ear without help from the blood or lymphatic circulation. Although the use of genetically modified cells as vectors of genes or pharmacotherapeutic agents is in the early stage, transplantation of genetically engineered cells able to secrete specific metabolic or humoral cues could augment pharmacologic immune modulation in the inner ear [87,89].

Delivery of genetically modified cells into the inner ear could pose a major challenge because of the anatomical characteristics of the inner ear. Monocytes and macrophages are able to migrate into the inner ear in both pathologic and normal conditions [53,57]. Thus, the human monocyte lineage could be isolated and cultured ex vivo and genetically manipulated. Intravenous administration of genetically modified monocytes could enable them to reach and migrate into the inner ear, although tissue or organ specificity could be a potential problem to overcome in clinical applications.

Apart from resident macrophages at the disease site, circulating monocytes are continuously recruited to meet the demands of the inflammatory response and the expression of chemokines, cytokines, and cell adhesion molecules. An alternative approach is to facilitate phagocytosis of loaded delivery vehicles by monocytes which passively targets the site of disease due to the mounting immune response. The active targeting response is most attractive and promising if the surface of the delivery vehicle can be decorated with a ligand that selectively interacts with their target receptors. Further research evaluating the use of monocytes as vehicles is desired.

Literature linking labyrinthitis, vestibular neuritis, and SNHL to the gut-microbiome-brain axis is not available, yet.

Conclusion

Recent advances in basic and clinical audiology and immunology research have been rapid. Particularly, the role of the innate immune system and the pathology of immune-mediated related inner ear disease is more evident now. Passive and preferably active target delivery of genetically modified monocytes is at present the most attractive option for the treatment of SNHL if the delivery vehicle can be decorated with a ligand that interacts with the target receptors. So, the future of the treatment of SNHL looks bright.

References

1. Thomson TL, Amadee R (2009) Vertigo: a review of common peripheral and central vestibular disorders. Ochsner J Spring 9(1): 20-26.
2. Retter M, Dicohon J (1996) Vestibular neuritis spares the inferior division of the vestibular nerve. Semicircular Brain 119(Pr3): 755-763.
3. Halmulgi GM (2005) Diagnosis and management of vertigo. Clin Med 5(2): 159-165.
4. McCabe BF (1979) Autoimmune sensorineural hearing loss. Ann Otol Rhinol. Laryng 88(Spt1): 585-89.
5. Sylvinemi P (1988) Vestibular neuritis. An otoneurological evaluation. Acta Otolaryngol Suppl 453: 1-72.
6. Arbushov V, Strupp R, Wasiky AK (2005) Detection of herpes simplex virus type 1 in vestibular nuclei. Neurology 55: 880-882.
7. Davis LE (1993) Viruses and vestibular neuritis: Review of human and animal studies. Acta Otolaryngol Suppl 503: 70-73.
8. Furkuta Y, Takasu T, Fukada S (1993) Latent herpes simplex virus type 1 in human vestibular ganglia. Acta Otolaryngol Suppl 503: 85-89.
9. Thel D, Arbushov V, Derfuss M (2001) Prevalence of HSV-1 LAT in human trigeminal, geniculate and vestibular ganglia and its implications for cranial nerve syndromes. Brain Pathol 11(4): 408-413.
10. Polack L, Book M, Smetana Z (2011) Herpes simplex virus type 1 in saliva of patients with vestibular neuritis: A preliminary study. Neurologist 17(6): 330-332.
11. Esaki S, Goshima H, Kimura S (2011) Auditory and vestibular defects induced by experimental labyrinthitis following herpes simplex virus in mice. Acta Otolaryngol 131: 694-691.
12. Ozugmus O, Sezen U, Kubilay E (2004) Connection between the facial-vestibular and cochlear nerve bundles within the internal auditory canal. J Anat 205: 65-75.
13. Fishman JM (2011) Corticosteroids effective in idiopathic facial nerve palsy (Bell’s palsy) but not necessarily in idiopathic acute vestibular dysfunction (vestibular neuritis). Laryngoscope 121: 2494-2495.
14. Fishman JM, Burgess C, Waddell A (2011) Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis). Cochrane Database Syst Rev 11(5): CD008607.
15. Wegner L, Van Benthem PM, Aarts ID (2012) Insufficient evidence for the effect of corticosteroid treatment on recovery of vestibular neuritis. Otolaryngol Head Neck Surg 147: 826-831.
16. Uffer DS Hegegman SC (2016) About the pathophysiology of acute unilateral vestibular deficit-vestibular neuritis (VN) or peripheral vestibulopathy (PVP)? J Vestibular Res 26: 311-317.
17. Karlberg M, Amertz M, Magnusson M (2004) Acute vestibular neuritis visualized by 3T magnetic resonance imaging with high doses gadolinium. Arch Otolaryngol Head Neck Surg 130(2): 229-32.
18. Hasnike K, Sekitoni T, Imate Y (1995) Enhanced MRI in patients with vestibular neuritis. Acta Otolaryngol Suppl519: 272-274.
19. Strupp M, Jager U, Muller Lisse V (1998) High resolution Gd-DTPA MR imaging of the inner ear in 60 patients with idiopathic vestibular neuritis: No evidence for contrast enhancement of the labyrinth or vestibular nerve. J Vest Res 8(6): 427-433.
20. Balah RW, Ishyma A, Wackym PA (1996) Vestibular neuritis: Clinical-pathologic correlation. Otolaryngol Head Neck Surg 114(4): 586-592.
21. Maranhao AS, Andrade JS, Godofredo RO (2013) Intratemporal complications of otitis media. Braz J Otorhinolaryngol 79(2): 141-149.
22. Leskien K, Jero J (2005) Acute complications of otitis media in adults. Clin Otol 30(6): 511-516.
23. Dubey SP, Larawin V (2007) Complications of chronic suppurative otitis media and their management. Laryngoscope 117(2): 264-267.
24. Osma U, Careghus S, Hosoglu S (2000) The complications of chronic otitis media report of 93 cases. J Laryngol Otol 114(2): 97-100.
25. Kangsaran J, Rosanant K, Ruckphaopunt N (1993) Extracranial and intracranial complications of suppurative otitis media: Report of 102 cases. J Otolaryngol Otol 107(11): 999-1004.
26. Penido NO, Andre Boriu A, Iha L (2005) Intracranial complications of otitis media: 15 years of experience in 33 patients. Otolaryngol Head Neck Surg 132(1): 37-42.

27. Floch JL, Tan W, Telang RS (2014) Markers of cochlear inflammation using MRL. Magn Reson Imaging 39(1): 150-161.

28. Hegarty JL, Patel S, Fischbein N (2002) The value of enhanced magnetic resonance imaging in the evaluation of endocochlear disease. Laryngoscope 112(1): 8-17.

29. Sone M, Mizuna T, Naganawa S (2009) Imaging analysis in cases with inflammation induced sensorineural hearing loss. Acta Otolaryngol 129(3): 239-243.

30. Dubrulle F, Kohler R, Vincent C (2010) Differential diagnosis and prognosis of T1-weighted post-gadolinium intralabyrinthine hyperintensities. Eur Radiol 20(11): 2628-2636.

31. Souza De Albuquerque A, Maranhao A, Godfredo VR (2016) Suppurative labyrinthitis associated with otitis media: 26 years experience. Braz J Otorhinolaryngol 82(1): 82-87.

32. Paparella MM, Sugiuira S (1967) The pathology of suppurative labyrinthitis. Ann Otol 76(3): 554-586.

33. Juhn SK, Hunter BA, Odland RM (2001) Blood-labyrinth barrier and fluid dynamics of the inner ear: Int Tinnitus J 7(2): 78-83.

34. Lemmerling MM, De Foe BM, Verbist V (2009) Imaging of inflammatory and infectious disease in the temporal bone. Neuroimaging Clin N Am 19(3): 321-337.

35. Mofatteh MR, Moghaddam F, Yousefi M (2018) A study of bacterial pathogens and antibiotic susceptibility patterns in chronic suppurative otitis media. J Laryngol Otol 132(1): 41-45.

36. Scott AM, Beller EM, Clark J (2018) Probiotics for preventing acute otitis media in children. Cochrane Acute Respiratory Infectious Group.

37. Shearer AE, Hildebrand MS, Smith RJ (2018) Hereditary Hearing Loss and Deafness Overview. In: Adam MP, Ardinger HH, Pagon RA (Eds.); GeneReviews Seattle, University of Washington Seattle, USA.

38. Kenneson A, Cannon MJ (2007) Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17(4): 253-276.

39. Kimberlin DW, Jester PM, Sanchez PJ (2015) Valganciclovir for symptomatic cytomegalovirus disease. NEJM 372: 933-943.

40. Yamashita T, Lin FR, Somera S (2013) Current concepts in age-related hearing loss: Epidemiology and mechanistic pathways. Hear Res 303: 30-30.

41. Sloan Heggen CM, Bierer AD, Shearer AL (2016) Comprehensive genetic testing in the clinical evaluation of 1119 patients with hearing loss. Hum Genet 135(4): 441-450.

42. Okano T (2014) Immune system of the inner ear: a novel therapeutic target for sensorineural hearing loss. Front Pharmacol 5: 205.

43. Harris JP, Ryan AF (1984) Immunobiology of the inner ear. Am J Otolaryngol 5(6): 418-425.

44. Trune DR, Canon B (2012) Corticosteroid therapy for hearing and balance disorders. Anot Rec ( Hoboken) 295(11): 1928-1943.

45. Kakehata S, Sasaki A, Oji K (2006) Comparison of intratympanic and intravenous dexametason treatment on sudden sensorineural hearing loss with diabetes. Otol Neurotol 27(5): 604-608.

46. Han CS, Park JR, Boo SH (2009) Clinical efficacy of initial intratympanic steroid treatment on sudden sensorineural hearing loss with diabetes. Otolaryngol Head Neck Surg 141(5): 572-578.

47. Moscicki RA, San Martin JE, Quintero CH (1994) Serum antibody to inner ear proteins in patients with progressive hearing loss: Correlation with disease activity and response to corticosteroid treatment. JAMA 272(8): 611-616.

48. McCabe BF (1989) Autoimmune inner ear disease therapy. Am J Otol 10: 196-197.

49. Dettmer M, Hegemann L, Hegemann SC (2011) Extratemporal Crohn’s disease mimicking autoimmune inner ear disease: A histopathological approach. Audiol Neurotol 16(1): 36-40.

50. Rask Andersen H, Stahle J (1979) Lymphocyte-macrophage activity in the endolympathic sac in the guinea pig. ORL J Otorhinolaryngol Relat Spes 41(4): 177-192.

51. Harris JP, Heydt J, Keithley EM (1997) Immunopathology of the inner ear: An update. Ann N Y Acad Sci 830: 166-178.

52. Lanf H, Ebihara Y, Schmiedt PA (2006) Contribution of bone marrow hematoipoietic stem cells to adult mouse inner ear: Mesenchymal cells and fibrocytes. J Comp Neurol 496(2): 187-201.

53. Okano T, Nakagawa T, Kita T (2008) Bone marrow-derived cells expressing Iba1 are constitutively present as resident tissue macrophages in the mouse cochlea. J Neurosci Res 86(8): 1758-1767.

54. Sato E, Shick HE, Ransohoff RM (2008) Repopulation of cochlear macrophages in murine hematopoietic progenitor cell chimeras: The role of CX3CR1. J Comp Neurol 506(6): 930-942.

55. Yughashi A, Sehiya T, Suzuki S (2004) Macrophage colony stimulating factor (M-CSF) protects spiral ganglion neurons following auditory nerve injury: Morphological and functional evidence. Exp Neurol 192(1): 167-177.

56. Vincent VA, Robinson CE, Sinek D (2002) Macrophage colony stimulating factor prevents NMDA-induced neuronal death in hippocampal organotypic cultures. J Neurochem 82(6): 1388-1397.

57. Hirose K, Discolo CM, Keasler JR (2005) Mononuclear phagocytes migrate into the murine cochlea after acoustic trauma. J Comp Neurol 489(2): 180-194.

58. Lawrence T, Natoli G (2011) Transcriptional regulation of macrophage polarization: Enabling diversity with identity. Nat Rev Immunol 11(1): 750-761.

59. Wynn TA, Chawla A, Pollard JW (2013) Macrophage biology in development, homeostasis and disease. Nature 496(7446): 445-455.

60. Burdo TH, Lackner A, Williams KC (2013) Monocytes, macrophages and their role in HIV neuropathogenesis. Immunol Rev 254(1): 102-113.

61. Lin CL, Lin SW, Weng SF (2013) Increased risk of sudden sensorineural hearing loss in patients with human immunodeficiency virus aged 18-35 years: A population-based cohort study. JAMA Otolaryngol Head Neck Surg 139(3): 251-255.

62. Assuiti LE, Lanzoni GM, Santos FC (2013) Hearing loss in people with HIV/AIDS and associated factors: An integrated review. Braz J Otorhinolaryngol 79(2): 248-255.

63. Smith MJ, Koch GL (1987) Differential expression of murine macrophage surface glycoprotein antigens in intracellular membranes. J Cell Sci 87(Pt 1): 113-119.
Global Journal of Otolaryngology

64. Ramprasad MP, Terpstra V, Kondatrenko N (1996) Cell surface macrophage receptors for oxidized low density lipoprotein. Proc Natl Acad USA 93(25): 14833-14838.

65. Hume DA, Ross II, Himes SR (2002) The mononuclear phagocyte system revisited. J Leukoc Biol 72(4): 621-627.

66. Imai Y, Ibata I, Ito D (1996) A novel gene iba1 in the major histocompatibility complex class 3 region encoding an EF hand protein expressed in a monocyte lineage. Biochem Biophys Res Commun 224(3): 855-862.

67. Zeitoun H, Beckmann JG, Arts HA (2005) Corticosteroid response and supporting cell antibody in autoimmune hearing loss. Arch Otolaryngol Head Neck Surg 131(8): 665-672.

68. Alexander TH, Weisman MH, Derebery JM (2009) Safety of high-dose corticosteroids for the treatment of autoimmune inner ear disease. Otol Neurotol 30(4): 433-448.

69. Spear SA, Schwartz SR (2011) Intratympanic steroids for sudden sensorineural hearing loss: A systematic review. Otolaryngol Head Neck Surg 145(4): 534-543.

70. Tahera Y, Meltser I, Johansson P (2006) NF-KappaB mediated glucocorticoid response in the inner ear after acoustic trauma. J Neurosci Res 83(6): 1066-1076.

71. Meltser I, Tahera Y, Canlon B (2009) Glucocorticoid receptor and mitogen-activated protein kinase activity after restraint, stress, and acoustic trauma. J Neurotrauma 26(10): 1835-1845.

72. MacArthur CJ, Kempton JR, DeGagne J (2008) Control of chronic otitis media and sensorineural hearing loss in C57H/Hej mice: Glucocorticoids vs mineralocorticoids. Otolaryngol Head Neck Surg 139(5): 646-653.

73. Garcia Berrocal JR, Vargas JA, Ramirez Camacho RA (1997) Deficiency of naive T cells in patients with sudden deafness. Arch Otolaryngol Head Neck Surg 123(7): 712-717.

74. Sally LH, Grimm M, Sismanis A (2001) Methotrexate in the management of immune mediated cochleovestibular disorders: Clinical experience with 53 patients. J Rheumatol 28(5): 1037-1040.

75. Matteson EL, Fabry DA, Facer GW (2001) Open trial of methotrexate as treatment for autoimmunity hearing loss. Arthritis Rheum 45(2): 146-150.

76. Harris JP, Weisman MH, Derebery JM (2003) Treatment of corticosteroid-responsive inner ear disease with methotrexate: Randomized controlled trial. JAMA 290(14): 1875-1883.

77. Lasak JM, Sataloff RT, Hawkshaw M (2001) Autoimmune inner ear disease: Steroid and cytotoxic drug therapy. Ear Nose Throat J 80(11): 808-811.

78. Mohler KM, Torrance DS, Smith CA (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151(3): 1548-1561.

79. Rahman MU, Poe DS, Choi HK (2001) Etanercept therapy for immune-mediated cochleovestibular disorders: Preliminary results in a pilot study. Otol Neurotol 22(5): 619-624.

80. Cohen S, Shoup A, Weisman MH (2005) Etanercept treatment for autoimmune inner ear disease: Results of a pilot placebo-controlled study. Otol Neurotol 26(5): 903-907.

81. Matteson EL, Choi HK, Poe DS (2005) Etanercept therapy for immune-mediated cochleovestibular disorders: A multi-center,open-label pilot study. Arthritis Rheum 53(3): 337-342.

82. Siddiqui MA, Scott LJ (2005) Infliximab: A review of its use in Crohn’s disease and rheumatoid arthritis. Drugs 65(15): 2179-2208.

83. Liu YC, Rubin R, Sataloff RT (2011) Treatment-refractory autoimmune sensorineural hearing loss: Response to infliximab. Ear Nose Throat J 90(1): 23-28.

84. Van Wijk F, Staeker H, Keithley E (2006) Local perfusion of the tumor necrosis factor alpha blocker infliximab tot he inner ear improves autoimmune inner ear disease: Results of a pilot study. Otol Neurotol 26(5): 903-907.

85. Mohr MJ, van Grols J, Ravid M, Kosicic J (2010) Successful use of adalimumab for treating rheumatoid arthritis with autoimmune sensorineural hearing loss: Two birds with one stone. J Rheumatol 37(5): 1080-1081.

86. Cohen S, Roland P, Shoup A (2011) A pilot study of rituximab in immune mediated inner ear disease. Audiol Neurotol 16(4): 214-221.

87. Hakuba N, Hata R, Morizane I (2005) Neural stem cells suppress the hearing threshold shift caused by cochlear ischemia. Neuroreport 16(14): 1545-1549.

88. Okano T, Nakagawa T, Kita T (2006) Cell gene delivery of brain-derived neurotrophic factor in the inner ear improves audiocortical plasticity. J Neurosci 26(44): 11533-11546.

89. Kesser BW, Lalwani AK (2009) Gene therapy and stem cell transplantation: Strategies for hearing restoration. Adv Otorhinolaryngol 66: 64-86.